Холангиоцеллюлярная карцинома сегодня. Литературный аналитический обзор

Автор: Ротин Даниил Леонидович

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Фундаментальная онкология и экспериментальная медицина

Статья в выпуске: 3 (14), 2015 года.

Бесплатный доступ

Холангиокарцинома (ХГК) представляет собой группу злокачественных опухолей с признаками дифференцировки в направлении эпителия желчных путей. Анатомически ХГК подразделяют на внутрипеченочные, воротные и дистальные. Данные подтипы различаются не только по локализации, но и по эпидемиологии, этиологии, патогенезу и лечению. Частота встречаемости и смертность от ХГК за последние десятилетия существенно выросли, в то время как выживаемость остается низкой. В разных географических областях вариации ХГК обусловлены различными факторами риска. В последние годы накоплены данные по генетическим изменениям клеток ХГК, кроме того обнаружено что строма этой опухоли содержит множество карциномазависимых фибробластов (КЗФ), стимулирующих развитие и рост опухоли. В характеристике и понимании онкогенезавнутрипеченочной ХГК и воротной ХГК отмечается существенный прогресс. Пациентов с внутрипеченочной ХГК обычно лечат хирургически. Для воротной ХГК основным методом лечения является трансплантация печени с неоадъювантной химиотерапией. Предлагаем обзор современного понимания эпидемиологии, патогенеза, классификации, взглядов на диагностику и лечение ХГК.

Еще

Холангиокарцинома, онкология, молекулярная патология, лечение опухолей

Короткий адрес: https://sciup.org/140223361

IDR: 140223361 | DOI: 10.18027/2224-5057-2015-3-3-16

Список литературы Холангиоцеллюлярная карцинома сегодня. Литературный аналитический обзор

Welzel TM, McGlynn KA, Hsing AW et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006; Vol. 98: p. 873-875.
Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; Vol. 8: p. 512-522.
Deoliveira ML, Schulick RD, Nimura Y, et al New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011; Vol. 53: p.1363-1371.
DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; Vol. 245: p.755-762.
Blechacz BG, GJ. Feldman: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9. Vol. 1. Saunders; 2010. Tumors of the Bile Ducts, Gallbladder, and Ampulla; pp. 1171-1176.
Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; Vol.61: p.1657-69.
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009; Vol.136: p.1134-1144.
Tyson GL, El-Serag HB. Risk factors forcholangiocarcinoma. Hepatology. 2011; Vol. 54: p.173-184.
Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; Vol. 24: p.115-125.
Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008; Vol. 24: p.349-356.
Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; Vol. 37: p.806-813.
Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; Vol. 10: p.77-82.
McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006; Vol. 15: p. 1198-1203.
Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; Vol. 33: p.1353-1357.
Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; Vol. 2: p.10.
Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us? Journal of Hepatology. 2012; Vol. 56: p.848-854.
Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013; Vol. 11: p.13-21.
Shin HR, Oh JK, Lim MK, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010; Vol. 25: p. 1011-1016.
Huang MH, Chen CH, Yen CM, et al. Relation of hepatolithiasis to helminthic infestation. J Gastroenterol Hepatol. 2005; Vol.20: p.141-146.
Edil BH, Cameron JL, Reddy S, et al. Choledochal cyst disease in children and adults: a 30-year singleinstitution experience. J Am Coll Surg. 2008; Vol. 206: p1000-1005. discussion 1005-8.
Mabrut JY, Bozio G, Hubert C, Gigot JF. Management of congenital bile duct cysts. Dig Surg. 2010; Vol. 27: p 12-18.
Kato I, Kido C. Increased risk of death in thorotrastexposed patients during the late follow-up period. Jpn J Cancer Res. 1987; vol. 78: p.1187-1192.
Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008; vol. 103: p.1716-720.
Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007; Vol. 102: p.1016-1021.
Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998; Vol. 28: p.921-925.
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; Vol. 57: p. 69-76.
Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005; Vol.128: p. 620-626.
Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; Vol. 5: p. 1221-1228.
Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007; Vol.120: p.638-641.
Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010; Vol.2: p.419-427.
Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008; Vol.47: p.1544-1556.
Tsuchiya A, Kamimura H, Tamura Y, et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. Cancer Lett. 2011; Vol.309: p.95-103.
Cardinale V, Carpino G, Reid L, et al. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol. 2012; Vol.4: p. 94-102.
Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012; Vol. 55: p.1876-1888.
Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; Vol.122: p.2911-2915.
Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012; Vol.122: p.3914-3918.
Holczbauer A, Factor VM, Andersen JB, et al. Modeling pathogenesis of primary liver cancer in lineagespecific mouse celltypes. Gastroenterology. 2013; Vol. 145: p. 221-231.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; Vol. 60: p.184-190.
Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999; Vol.30: p.1128-1133.
Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005; Vol.128: p.2054-2065.
Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004; Vol. 64: p. 3517-3524.
Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; Vol.42: p.1329-38.
Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006; Vol. 44: p.1055-1065.
Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013.
Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; Vol.144: p.829-840.
Isomoto H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007; Vol. 132: p.384-396.
Yoon JH, Gwak GY, Lee HS, et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004; Vol. 41: p. 808-814.
Kiguchi K, Carbajal S, Chan Ket al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001; Vol.61: p.6971-6976.
Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006; Vol. 119: p. 477-483.
Nishimura K, Kitamura M, Miura H, et al. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate. 1999; Vol. 41: p. 145-153.
Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumorderived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997; Vol.57: p.3305-3313.
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; Vol. 7: p. 504-516.
Lai GH, Radaeva S, Nakamura T, Sirica AE. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver. Hepatology. 2000; Vol.31: p.1257-1265.
Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011; Vol.105: p.131-138.
Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producingcholangiocarcinoma. Hepatology. 1999; Vol. 29: p.1453-1462.
Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002; Vol.122: p.985-993.
Yoon JH, Canbay AE, Werneburg NW, et al. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology. 2004; Vol.39: p. 732-738.
Kuver R. Mechanisms of oxysterol-induced disease: insights from the biliary system. Clin Lipidol. 2012; Vol. 7: p. 537-548.
Nachtergaele S, Mydock LK, Krishnan K, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012; Vol. 8: p. 211-220.
Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011; Vol. 54: p. 2076-2088.
Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012; Vol. 28: p.266-272.
McKay SC, Unger K, Pericleous S, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) 2011; Vol.13: p.309-319.
Koo SH, Ihm CH, Kwon KC, et al. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001; Vol.130: p.22-28.
Uhm KO, Park YN, Lee JY, et al. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2005; Vol.157: p.37-41.
Lee JY, Park YN, Uhm KO, et al. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci. 2004; Vol.19: p.682-687.
Wong N, Li L, Tsang K, Lai PB, et al. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol. 2002; Vol.37: p. 633-639.
Homayounfar K, Gunawan B, Cameron S, et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol. 2009; Vol.40: p. 834-842.
Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; Vol. 44: p.690-693.
Xu RF, Sun JP, Zhang SR, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011; Vol.65: p.22-26.
Ohashi K, Nakajima Y, Kanehiro H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995; Vol.109: p.1612-1617.
Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; Vol.142: p.1021-1031.
Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer. 1992; Vol.69: p.1115-1118.
Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005; Vol.25: p.704-716.
Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; Vol.43: p.1552-1558.
Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; Vol.17: p.72-79.
Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2012.
Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010; Vol. 17: p. 215-216.
Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; Vol.340: p.626-630.
Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; Vol.340: p.622-626.
Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepaticcholangiocarcinoma. Hepatology. 2012; Vol.56: p.1792-1803.
Chen L, Yan HX, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009; Vol. 50: p. 358-369.
Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer discovery. 2013; Vol.3: p.636-647.
Yamanaka S, Olaru AV, An F, et al. MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis. 2012; Vol.44: p.589-596.
Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; Vol.130: p.2113-2129.
Hofmann JJ, Zovein AC, Koh H, et al. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development. 2010; Vol.137: p.4061-4072.
Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013; Vol.23: p.784-795.
Jinawath A, Akiyama Y, Sripa B, Yuasa Y. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2007; Vol.133: p.271-278.
El Khatib M, Kalnytska A, Palagani V, et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology. 2013; Vol.57: p.1035-1045.
Sirica AE, Nathanson MH, Gores GJ, Larusso NF. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M and Lillian Stratton Basic Research Single-TopicConference. Hepatology. 2008; Vol.48: p. 2040-2046.
Tanaka S, Sugimachi K, Kameyama T, et al. WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology. 2003; Vol.37: p.1122-1129.
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; Vol.501: p.346-354.
Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012; Vol. 9: p.44-54.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; Vol.6: p.392-401.
Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology. 2010; Vol.51: p.1438-1444.
Okabe H, Beppu T, Hayashi H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009; Vol.16: p.2555-2564.
Quante M, Tu SP, Tomita H, et al. Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011; Vol.19: p.257-272.
Li T, Li D, Cheng L, et al. Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma. Ann Surg Oncol. 2010; Vol. 17: p.1937-1944.
Sato Y, Harada K, Itatsu K, et al. Epithelialmesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010; Vol.177: p.141-152.
Korita PV, Wakai T, Ajioka Y, et al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 2010; Vol.30: p.2279-2285.
Cadamuro M, Nardo G, Indraccolo S, et al. Plateletderived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013
Fingas CD, Mertens JC, Razumilava N, et al. Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012; Vol.32: p. 400-409.
Utispan K, Thuwajit P, Abiko Y, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010; Vol.9: p.13.
Baril P, Gangeswaran R, Mahon PC, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3kpathway. Oncogene. 2007; Vol.26: p.2082-2094.
Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol. 2010; Vol.16: p.713-722.
Ohira S, Sasaki M, Harada K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol. 2006; Vol.168: p.1155-1168.
Leelawat K, Leelawat S, Narong S, Hongeng S. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol. 2007; Vol.13: p.1561-1568.
Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996; Vol. 23: p. 1341-1344.
Prakobwong S, Yongvanit P, Hiraku Y, et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010; Vol.127: p.2576-2587.
Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008; Vol.37: p.154-158.
Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013; Vol. 73: p. 897-907.
Ko KS, Peng J, Yang H. Animal models of cholangiocarcinoma. Curr Opin Gastroenterol. 2013; Vol.29: p.312-318.
Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 2005; Vol.65: p.11437-11446.
Pawar P, Ma L, Byon CH, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res. 2009; Vol.15: p. 1288-1296.
Tang T, Zheng JW, Chen B, et al. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int. 2007; Vol.6: p. 303-307.
Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating betacatenin. Gastroenterology. 2012; Vol.143: p.246-526.
Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 2011; Vol. 54: p.2089-2098.
Zhang K, Chen D, Wang X, et al. RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via Upregulating PUMA. Int J Mol Sci. 2011; Vol.12: p.385-400.
Obchoei S, Weakley SM, Wongkham S, et al. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 2011; Vol.10: p.102.
Hou YJ, Dong LW, Tan YX, et al. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.Lab Invest.2011; Vol. 91: p.1146-1157.
Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liverspecific disruption of Smad4 and Pten in mice. J Clin Invest. 2006; Vol.116: p.1843-1152.
Farazi PA, Zeisberg M, Glickman J, et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006; Vol. 66: p. 6622-6627.
Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010; Vol.107: p.1431-1436.
Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; Vol.107: p.8248-8253.
O’Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012; Vol.72: p.1557-1567.
Sirica AE, Zhang Z, Lai GH, et al. A novel "patientlike" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008; Vol. 47: p.1178-1190.
Campbell DJ, Dumur CI, Lamour NF, et al. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res. 2012; Vol.42: p.1119-1130.
Fava G, Alpini G, Rychlicki C, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 2008; Vol.68: p.6752-6761.
Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011; Vol.141: p.378-388.
Plengsuriyakarn T, Eursitthichai V, Labbunruang N, et al. Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/dimethylnitrosamine-induced hamsters. Asian Pac J Cancer Prev. 2012; Vol.13: p.87-90.
Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003; Vol. 10: p.288-291.
Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellularcarcinoma. Hepatology. 2009; Vol.50: p.791-798.
Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford) 2008; Vol. 10: p.106-109.
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; Vol.48: p.308-321.
Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000; Vol. 95: p. 204-207.
Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011; Vol.17: p.934-942.
Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; Vol.248: p.84-96.
Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009; Vol. 16: p.3048-3056.
Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment. J Gastrointest Surg. 2011; Vol.15: p.608-613.
Fabris L, Cadamuro M, Moserle L, et al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology. 2011; Vol.54: p.890-899.
Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013; Vol.29: p.324-328.
Valle J, Wasan H, Palmer DH, et al. Investigators ABCT. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; Vol.362: p.1273-1281.
Yamashita Y, Takahashi M, Kanazawa S, et al. Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography. Acta Radiol. 1992; Vol.33: p.351-355.
Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination.HPB (Oxford) 2011; Vol.13: p.356-360.
Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.Gastroenterology.2006; Vol.131: p.1064-1072.
Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of http://cholangiocarcinoma.Am J Gastroenterol.2011; Vol.106:2023-2028.
Barr Fritcher EG, Voss JS, Jenkins SM, et al. Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.Cancer Cytopathol.2013.
Nagorney DM, Kendrick ML. Hepatic resection in the treatment of hilar cholangiocarcinoma.Adv Surg.2006; Vol.40: p.159-171.
Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.Gastroenterology.2012; Vol.143: p.88-98.
Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011; Vol.146: p.683-689.
Geynisman DM, Catenacci DV. Toward personalized treatment of advanced biliary tract cancers. Discov Med. 2012; Vol.14: p.41-57.

Еще

Статья обзорная